Shimizu Mikiko, Hashiguchi Masayuki, Shiga Tsuyoshi, Nakamura Koichi, Tamura Hiro-omi, Mochizuki Mayumi
Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 15;985:172-9. doi: 10.1016/j.jchromb.2015.01.013. Epub 2015 Jan 22.
This paper describes a sensitive, reliable method to determine pilsicainide (PLC) levels in microscale sample volumes of human biological fluids using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with electrospray ionization (ESI). PLC and quinidine as an internal standard were extracted with diethylether from 0.1mL of alkalinized biological fluids. The extract was injected into an analytical column (l-column 2 ODS, 75mm×2.1mm i.d.). The mobile phase for separation consisted of 5mM ammonium acetate (pH 4.5)/methanol (4:1, v/v) and was delivered at a flow rate of 0.2mL/min. The drift voltage was 100V. The sampling aperture was heated at 120°C and the shield temperature was 260°C. The ion transitions used to monitor analytes were m/z 273→m/z 110 for PLC and m/z 325→m/z 79 for quinidine. The total time for chromatographic separation was less than 8min. The validated concentration ranges of this method for PLC were 5-2000ng/mL in plasma, 5-500ng/mL in ultrafiltered plasma solution, and 25-2000ng/mL in urine. Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively. Intra- and interday coefficients of variation for PLC were less than 6.0% and 4.3% in plasma, 6.1% and 3.7% in ultrafiltered plasma solution, and 5.4% and 2.5% in urine at the above concentration ranges, respectively. The lower limit of quantification for PLC in plasma, ultrafiltered plasma solution, and urine were 5ng/mL, 5ng/mL, and 25ng/mL, respectively. This method can be applied to pharmacokinetic study and therapeutic drug monitoring in special populations such as neonates, infants, and the elderly by making effective use of residual samples used for general clinical laboratory testing.
本文描述了一种灵敏、可靠的方法,使用带电喷雾电离(ESI)的液相色谱 - 串联质谱(LC - MS/MS)来测定微量人体生物流体样本中的吡西卡尼(PLC)水平。PLC和作为内标的奎尼丁用乙醚从0.1mL碱化的生物流体中萃取。萃取物注入分析柱(l - column 2 ODS,75mm×2.1mm内径)。分离的流动相由5mM醋酸铵(pH 4.5)/甲醇(4:1,v/v)组成,流速为0.2mL/min。漂移电压为100V。采样孔加热至120°C,屏蔽温度为260°C。用于监测分析物的离子跃迁为PLC的m/z 273→m/z 110和奎尼丁的m/z 325→m/z 79。色谱分离的总时间少于8分钟。该方法对PLC在血浆中的验证浓度范围为5 - 2000ng/mL,在超滤血浆溶液中为5 - 500ng/mL,在尿液中为25 - 2000ng/mL。PLC在血浆、超滤血浆溶液和尿液中的平均回收率分别为93.2 - 99.7%、91.4 - 100.6%和93.9 - 104.7%。在上述浓度范围内,PLC在血浆中的日内和日间变异系数分别小于6.0%和4.3%,在超滤血浆溶液中分别为6.1%和3.7%,在尿液中分别为5.4%和2.5%。PLC在血浆、超滤血浆溶液和尿液中的定量下限分别为5ng/mL、5ng/mL和25ng/mL。通过有效利用用于一般临床实验室检测的残留样本,该方法可应用于新生儿、婴儿和老年人等特殊人群的药代动力学研究和治疗药物监测。